For people with acute myeloid leukemia (AML), a new analysis of over 6,000 patients suggests that certain targeted drugs may offer real benefits. The study looked at three FLT3 inhibitors: gilteritinib, midostaurin, and quizartinib. These drugs work by blocking a specific protein that helps cancer cells grow.
Gilteritinib and midostaurin were linked to higher rates of complete remission. Gilteritinib nearly doubled the odds of remission compared to standard care, while midostaurin increased the odds by about 30%. Gilteritinib and quizartinib also appeared to help people live longer, reducing the risk of death by about 30% and 27%, respectively.
But these benefits came with side effects. Patients on the FLT3 inhibitors had a higher risk of low white blood cell counts, anemia, fatigue, and other issues. The analysis combined results from several clinical trials, which strengthens the evidence, but it's still an indirect comparison. More head-to-head studies would help clarify which drug works best for whom.